

November 18, 1981

Solomon Sobel, M.D.  
Division of Metabolism  
and Endocrine Drug Products, HFD-130  
FDA  
5600 Fishers Lane  
Rockville, Maryland 20857

Dear Dr. Sobel,

This letter is in response to your letter of October 30, regarding IND 16,906, and our study of DGAVP. I have written to the manufacturers in Holland and requested their advice as to whether they have made any further in assaying the 3-4% of material not identifies in the present DGAVP formulation. Their reply will be sent as soon as received.

To date, in our normal volunteers, we have observed no untoward effects of the use of this formulation in acute trials.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry